Graphene Investments SAS Has $2.67 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Graphene Investments SAS cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 15.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 5,500 shares of the pharmaceutical company's stock after selling 1,000 shares during the quarter. Graphene Investments SAS's holdings in Vertex Pharmaceuticals were worth $2,667,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Mascagni Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $31,000. Truvestments Capital LLC grew its stake in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. Minot DeBlois Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, Prestige Wealth Management Group LLC boosted its holdings in shares of Vertex Pharmaceuticals by 45.5% in the 4th quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock valued at $45,000 after buying an additional 35 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several analyst reports. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Leerink Partners reaffirmed a "market perform" rating and issued a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Erste Group Bank cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Morgan Stanley cut their price target on Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a report on Friday, June 20th. Fourteen investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $513.14.

Vertex Pharmaceuticals Stock Down 0.5%

Shares of VRTX opened at $443.40 on Friday. The firm has a 50 day simple moving average of $455.45 and a two-hundred day simple moving average of $459.02. The company has a market cap of $113.87 billion, a P/E ratio of -113.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company posted $4.76 EPS. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.